| Description: |
Gaëtan Deslee,1 Héloïse Russo,2 Caroline Fabry-Vendrand,2 David Koskas,2 Gabriel Thabut,2 John P Bell,3 Melissa Caplen,4 Prachi Devendra Bhatt,4 Jennifer Carioto,4 Bruce Pyenson,4 Pierre-Régis Burgel5 1Service de Pneumologie, INSERM UMRS-1250, Hospital Universitaire de Reims, Reims, France; 2Astrazeneca, Medical Department, Courbevoie, France; 3AstraZeneca, Global Respiratory & Immunology, BioPharmaceuticals Medical, Cambridge, UK; 4Milliman,New York, NY, USA; 5Service de Pneumologie, Hôpital Cochin, Assistance Publique Hôpitaux de Paris et Université Paris Cité, Institut Cochin, INSERM U1016, Paris, FranceCorrespondence: Pierre-Régis Burgel, Service de Pneumologie, Hôpital Cochin, 27 rue du Faubourg Saint Jacques, Paris, 75014, France, Email pierre-regis.burgel@aphp.frBackground: COPD is the seventh-leading cause of death in France. The randomized controlled trials ETHOS (NCT02465567) and IMPACT (NCT02164513) have demonstrated a reduction in exacerbations (primary endpoint) and suggest a decrease in mortality (secondary endpoint) with single-inhaler triple therapy (SITT)—containing a long-acting beta-2 agonist, long-acting anticholinergics, and an inhaled corticosteroid—in patients with COPD. No study has evaluated the potential impact of increased SITT use in France.Objective: To evaluate the impact of increased SITT use in COPD on exacerbations, mortality, and medical costs in France.Methods: A stochastic model was constructed using GOLD therapeutic recommendations and literature data on patient characteristics, prevalence, incidence, treatment distribution, COPD severity and treatment changes, mortality, and exacerbations to model the French COPD population. Two scenarios were studied: Status Quo (no increase in SITT use) and Increased SITT, using the GOLD stage and exacerbation history to initiate SITT treatment in modeled patients, considering the annual probabilities of transitioning from one GOLD stage to another over a 10-year period.Results: Increased SITT use compared to the ... |